Oral tobramycin in ulcerative colitis: effect on maintenance of remission
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
SUMMARY: Oral tobramycin for 7 days has been shown to be of benefit as an adjunct to conventional medication in acute ulcerative colitis. Eighty‐one patients (40 who had received tobramycin; 41 placebo) who had been enrolled in a double‐blind placebo‐controlled trial of this drug in acute disease were subsequently followed to determine whether this short‐term benefit persisted. Relapse was defined as a liquid stool frequency of three times daily with rectal bleeding. Results were analysed by the log‐rank test on Kaplan‐Meier survival curves. Treatment failure was defined as a lack of response by the end of the acute trial period, or subsequent relapse. In a second analysis, only those entering remission at the end of the acute trial were considered, and followed to relapse. Although at the start of the follow‐up period significantly fewer patients in the tobramycin group had failed (failed: tobramycin 9, placebo 24; not failed tobramycin 31; placebo 17;P= 0.001), the failure‐free survival curves subsequently converged and did not differ significantly. After 1 and 2 years, the failure‐free survival rates were 40% (S.E. = 7.8%) and 20% (S.E. = 6.3%) for the tobramycin group and 24% (S.E. = 6.7%) and 12% (S.E. = 5.1%) for the placebo group. When only those entering remission were considered, there was no significant difference in the relapse rates in the two groups. Benefit from tobramycin is therefore short‐lived and may reflect short‐term changes in the faecal flora.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Treatment of ulcerative colitis by implantation of normal colonic flora
Bennet, J., & Brinkman, M. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91183-5 · Cited by 304
Cited by
Rembacken, B., Snelling, A., Hawkey, P., Chalmers, D., & Axon, A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)06343-0 · Cited by 1,101
Self-citationAntibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis
Khan, K. J., Ullman, T. A., Ford, A. C., Abreu, M. T., Abadir, A., Marshall, J. K., Talley, N. J., & Moayyedi, P. (2011) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.72 · Cited by 569
Malchow, H. A. (1997) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-199712000-00021 · Cited by 403
Turner, D., Levine, A., Escher, J. C., Griffiths, A. M., Russell, R. K., Dignass, A., Dias, J. A., Bronsky, J., Braegger, C. P., Cucchiara, S., et al. (2012) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0b013e3182662233 · Cited by 382
ESPEN guideline on Clinical Nutrition in inflammatory bowel disease
Bischoff, S. C., Bager, P., Escher, J., Forbes, A., Hébuterne, X., Hvas, C. L., Joly, F., Klek, S., Krznaric, Z., Ockenga, J., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2022.12.004 · Cited by 367
Metadata
- Authors
- LOBO, A. J., BURKE, D. A., SOBALA, G. M., & AXON, A. T. R.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 1993-04
- Volume
- 7
- Issue
- 2
- Pages
- 155-158
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2060859971
- Cited by
- 74
- References
- 1
- FWCI
- 0.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Oral tobramycin in ulcerative colitis: effect on maintenance of remission. https://app.cochat.ai/papers/10.1111/j.1365-2036.1993.tb00084.x
- The paper
- LOBO, A. J., BURKE, D. A., SOBALA, G. M., & AXON, A. T. R. (1993). Oral tobramycin in ulcerative colitis: effect on maintenance of remission. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/j.1365-2036.1993.tb00084.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.